Abstract 1912
Background
The overall benefit from systemic treatments in advanced STS remains modest despite advances in cancer therapies. PDX models may help as avatars in guiding individualized drug use decisions.
Methods
In this prospective single center trial, fresh tumors from patients (pts) with suspected or recently diagnosed STS were engrafted into immunodeficient mice avatars (TumorGraft; Champions Oncology) and tested against a number of standard or non-licensed agents. PDX drug sensitivity profiles were then compared with real-life treatment outcomes.
Results
Of 18 patients enrolled, 3 patients were excluded (consent withdrawal/non-sarcomas). Patient baseline characteristics are summarized in the table. Rate of engraftment was 40% (6/15 pts), while the median time from biopsy to availability of drug sensitivity profile was 379 days (186 – 421). In patients with available drug sensitivity profile (9 different drugs involving 6 pts), the mouse avatar correctly predicted the drug efficacy or lack thereof of drugs in 7 of 9 drug selection time-points (78%) and in 5 of 6 patients (83%).Table:
1718P Patient baseline characteristics
Item | Eligible patients (n = 15) | Engrafted patients (n = 6) |
---|---|---|
Median age (range) | 57 (23-76) | 57 (45-69) |
Gender (M:F) | 8:7 | 3:3 |
Subtype - Liposarcoma - Leiomyosarcoma -UPS -Others | 5 3 1 6 | 2 2 1 1 |
Conclusions
PDX avatars can accurately predict drug response in STS pts. The rate of engraftment and time taken to produce drug sensitivity profiles are limitations for using this platform in guiding treatment for individual patients in real time. Nonetheless, the high degree of clinical predictability of this PDX platform may offer therapeutic value for personalized oncology approaches.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Albiruni Razak.
Funding
Mount Sinai Sarcoma Foundation.
Disclosure
G. Paris: Full / Part-time employment: champions oncology. M. Mancini: Travel / Accommodation / Expenses, Shareholder / Stockholder / Stock options, Full / Part-time employment: Champions Oncology. A.R.R. Albiruni: Honoraria (self), Advisory / Consultancy, Research grant / Funding (self): Boehringer Ingelheim; Advisory / Consultancy, Research grant / Funding (self): Lilly; Advisory / Consultancy, Research grant / Funding (self): Merck; Research grant / Funding (self): CASI Pharmaceuticals; Research grant / Funding (self): Novartis; Research grant / Funding (self): Deciphera; Research grant / Funding (self): Kayopharm Therapeutics; Research grant / Funding (self): Pfizer; Research grant / Funding (self): Roche/ Genentech; Research grant / Funding (self): Boston Biomedical; Research grant / Funding (self): Bristol-Myers Squibb; Research grant / Funding (self): MedImmune; Research grant / Funding (self): Amgen; Research grant / Funding (self): GlaxoSmithKline; Research grant / Funding (self): Blueprint Medicines; Research grant / Funding (self): AbbVie; Research grant / Funding (self): Adaptimmune. All other authors have declared no conflicts of interest.
Resources from the same session
3309 - Heat Shock Protein 90 chaperones and Protein Kinase D3 regulates androgen-independent prostate cancer development
Presenter: Attila Varga
Session: Poster Display session 1
Resources:
Abstract
3441 - The SWI/SNF driven reprograming for the AR cistrome is NSD2 dependent
Presenter: Katia Ruggero
Session: Poster Display session 1
Resources:
Abstract
1659 - IGF1R inhibition affects the survival of HT29 cancer cells by alterations of the TLR9- and autophagy signaling
Presenter: Györgyi Műzes
Session: Poster Display session 1
Resources:
Abstract
1379 - Characterization of atypical dMMR (deficient MisMatch Repair) tumors: a study from a large cohort of 4948 cases
Presenter: Marion Jaffrelot
Session: Poster Display session 1
Resources:
Abstract
1657 - Modulation of TLR9-dependent autophagy response via inhibition of c-Met signaling influences the survival of HT29 cancer cells
Presenter: Ferenc Sipos
Session: Poster Display session 1
Resources:
Abstract
3045 - Positive Feedback Activation of Notch Signal by Obesity Enhances Colorectal Tumorigenicity
Presenter: Dake Chu
Session: Poster Display session 1
Resources:
Abstract
2285 - The Pathological and Functional Roles of BRPF1 in Hepatocellular Carcinoma
Presenter: Lai Hung Carol Cheng
Session: Poster Display session 1
Resources:
Abstract
3210 - Protein tyrosine phosphatase non-receptor type 3 (PTPN3) could be a new therapeutic target for pancreatic cancer.
Presenter: Akio Yamasaki
Session: Poster Display session 1
Resources:
Abstract
3920 - A Novel bispecific BCMAxCD3 T cell engaging antibody that treat multiple myeloma (MM) with minimal cytokine serection
Presenter: Zhenyu Li
Session: Poster Display session 1
Resources:
Abstract
2691 - Quantitative spatial profiling of lymphocyte-activation gene 3 (LAG-3)/major histocompatibility complex class II (MHC II) interaction in gastric and urothelial tumors
Presenter: Cyrus Hedvat
Session: Poster Display session 1
Resources:
Abstract